标题
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells
作者
关键词
-
出版物
ANTI-CANCER DRUGS
Volume -, Issue -, Pages -
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-10-16
DOI
10.1097/cad.0000000000001549
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
- (2023) Georgia Gomatou et al. Cancers
- Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC
- (2023) Weiwei Peng et al. Frontiers in Oncology
- Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells
- (2023) Laurence Booth et al. ANTI-CANCER DRUGS
- Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib
- (2021) Paul Dent et al. BIOCHEMICAL PHARMACOLOGY
- Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling
- (2020) Paul Dent et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]
- (2020) Paul Dent et al. CELLULAR SIGNALLING
- Irreversible kinase inhibitors targeting to cysteine residues and their applications in cancer therapy
- (2020) Debasis Das et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer
- (2020) Laurence Booth et al. BIOCHEMICAL PHARMACOLOGY
- Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
- (2019) Paul Dent et al. ONCOGENE
- Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
- (2019) Sarah W. Gordon et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Emerging role of the Jun N-terminal kinase interactome in human health
- (2018) Xiao-Xi Guo et al. CELL BIOLOGY INTERNATIONAL
- Neratinib augments the lethality of [regorafenib + sildenafil]
- (2018) Laurence Booth et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
- (2017) Laurence Booth et al. Oncotarget
- [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
- (2017) Laurence Booth et al. Oncotarget
- Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function
- (2016) Laurence Booth et al. Oncotarget
- Phase I study of pemetrexed with sorafenib in advanced solid tumors
- (2016) Andrew Poklepovic et al. Oncotarget
- [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
- (2016) Laurence Booth et al. Oncotarget
- Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
- (2016) Laurence Booth et al. Oncotarget
- Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
- (2015) Mehrad Tavallai et al. JOURNAL OF CELLULAR PHYSIOLOGY
- GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases
- (2015) Jane L. Roberts et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
- (2012) M. Danielle Bareford et al. CANCER BIOLOGY & THERAPY
- Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery
- (2012) Brian I. Carr et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells
- (2011) M. D. Bareford et al. CANCER RESEARCH
- Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
- (2010) Margaret A. Park et al. CANCER BIOLOGY & THERAPY
- Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway
- (2010) M. A. Park et al. CANCER RESEARCH
- BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing
- (2009) A. P. Martin et al. MOLECULAR PHARMACOLOGY
- Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms
- (2009) T. Walker et al. MOLECULAR PHARMACOLOGY
- Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
- (2008) G. Zhang et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now